Form 4: Achieve Life Sciences Director Thomas Sellig Granted 31,500 Stock Options

Achieve Life Sciences, Inc. Director Thomas Sellig was granted 31,500 stock options with an exercise price of $3.83, vesting by June 2026.

Summary

• Thomas Sellig, a Director of ACHIEVE LIFE SCIENCES, INC. (ACHV), was granted 31,500 stock options.
• The transaction date for this grant was June 6, 2025.
• Each option has an exercise price of $3.83.
• The options will vest 100% on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders.
• The options have an expiration date of June 6, 2035.
• Following this transaction, Thomas Sellig beneficially owns 31,500 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally viewed as a neutral to slightly positive event, as it aligns the director's interests with shareholders, but it is a routine compensation matter rather than a significant operational or financial announcement.

Positives

• The grant of stock options to Director Thomas Sellig aligns his interests with those of shareholders, as the value of the options increases with the company's stock price.
• The options have a long expiration date (June 6, 2035), providing a long-term incentive for the director.

Future Outlook

The document indicates that the granted stock options will vest 100% on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders, providing a future incentive for the director.

Industry Context

Form 4 filings are standard regulatory disclosures for insider transactions, such as the grant of equity compensation to directors and officers. This type of compensation is a common practice across various industries, including biotechnology and pharmaceuticals, to incentivize long-term performance and align management interests with shareholders.

Comparison to Industry Standards

• This Form 4 reports a routine grant of stock options to a director, which is a standard component of executive and director compensation packages across publicly traded companies. The specific number of options and exercise price would typically be benchmarked against peer companies in the biotechnology sector, considering the company's size, stage of development, and the director's role and tenure. Without specific peer compensation data, a direct comparison is not feasible from this document alone.

Related Party Transactions

• The grant of 31,500 stock options to Thomas Sellig, a Director of Achieve Life Sciences, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's long-term interests with those of shareholders, potentially leading to better governance and performance.

Next Steps

• The stock options will become fully vested on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders.
• Following vesting, the director will have the right to exercise these options to acquire common stock at the specified exercise price until the expiration date of June 6, 2035.

Key Dates

Keywords

Achieve Life Sciences, ACHV, Form 4, insider transaction, stock options, director compensation, beneficial ownership, equity grant